Acurx Pharmaceuticals LLC ACXP

NAS: ACXP | ISIN: US00510M1045   2/04/2026
3,680 USD (-5,40%)
(-5,40%)   2/04/2026

30 maart 2026 · Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors · Persbericht

13 maart 2026 · Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update · Persbericht

9 maart 2026 · Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection · Persbericht

16 februari 2026 · Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update · Persbericht

2 februari 2026 · USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors · Persbericht

18 november 2025 · Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals · Persbericht

12 november 2025 · Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update · Persbericht

10 november 2025 · Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens · Persbericht

28 oktober 2025 · Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference · Persbericht

27 oktober 2025 · Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update · Persbericht

9 oktober 2025 · Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors · Persbericht

30 september 2025 · Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection · Persbericht

3 september 2025 · Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules · Persbericht

12 augustus 2025 · Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update · Persbericht

31 juli 2025 · Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split · Persbericht

24 juli 2025 · Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update · Persbericht

19 juni 2025 · /C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ · Persbericht

18 juni 2025 · Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds · Persbericht

17 juni 2025 · Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI · Persbericht

9 juni 2025 · Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference · Persbericht

Mijn selecties